BIOMARIN PHARMACEUTICAL INC (BMRN) Free cash flow
- Free cash flow · 12 months (USD): Value $738.18M; Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value 21.67%; Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | $738.18M | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. $857.09M − $118.91M ≈ $738.18M |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | 21.67% | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. $738.18M ÷ $3.41B × 100 ≈ 21.67% |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $857.09M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 11.75× | Operating cash flow / net income. Period ending 2026-06-30. $857.09M ÷ $72.97M ≈ 11.75× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | 857.09M USD | Net Cash Provided by (Used in) Operating Activities · Net Cash Provided by (Used in) Operating Activities, Continuing Operations |
| Capital spending | 118.91M USD | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | 738.18M USD | Net Cash Provided by (Used in) Operating Activities · Net Cash Provided by (Used in) Operating Activities, Continuing Operations · Payments to Acquire Property, Plant, and Equipment |
| Revenue | 3.41B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | 72.97M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $738.18M | (m) | $857.09M | $118.91M | (m) | $3.41B | (m) | $72.97M | (m) | (m) | 21.67% | 11.75× |
| 2026-03-31 | $767.06M | (m) | $874.25M | $107.19M | (m) | $3.24B | (m) | $268.74M | (m) | (m) | 23.66% | 3.25× |
| 2025-12-31 | $724.96M | (m) | $827.99M | $103.04M | (m) | $3.22B | (m) | $348.90M | (m) | (m) | 22.51% | 2.37× |
| 2025-09-30 | $832.13M | (m) | $913.98M | $81.85M | (m) | $3.09B | (m) | $520.42M | (m) | (m) | 26.89% | 1.76× |
| 2025-06-30 | $694.91M | (m) | $766.77M | $71.86M | (m) | $3.06B | (m) | $657.24M | (m) | (m) | 22.68% | 1.17× |
| 2025-03-31 | $624.18M | (m) | $700.26M | $76.09M | (m) | $2.95B | (m) | $523.88M | (m) | (m) | 21.16% | 1.34× |
| 2024-12-31 | $487.42M | (m) | $572.84M | $85.42M | (m) | $2.85B | (m) | $426.86M | (m) | (m) | 17.08% | 1.34× |
| 2024-09-30 | $319.89M | (m) | $414.70M | $94.81M | (m) | $2.75B | (m) | $322.29M | (m) | (m) | 11.62% | 1.29× |
| 2024-06-30 | $230.78M | (m) | $328.86M | $98.08M | (m) | $2.59B | (m) | $256.59M | (m) | (m) | 8.92% | 1.28× |
| 2024-03-31 | $181.82M | (m) | $280.16M | $98.34M | (m) | $2.47B | (m) | $205.46M | (m) | (m) | 7.36% | 1.36× |
| 2023-12-31 | $62.57M | (m) | $159.26M | $96.69M | (m) | $2.42B | (m) | $167.65M | (m) | (m) | 2.59% | 0.95× |
| 2023-09-30 | $35.10M | (m) | $138.56M | $103.46M | (m) | $2.31B | (m) | $147.02M | (m) | (m) | 1.52% | 0.94× |
| 2023-06-30 | $50.21M | (m) | $161.24M | $111.03M | (m) | $2.23B | (m) | $99.99M | (m) | (m) | 2.25% | 1.61× |
| 2023-03-31 | $30.80M | (m) | $147.40M | $116.60M | (m) | $2.17B | (m) | $71.61M | (m) | (m) | 1.42% | 2.06× |
| 2022-12-31 | $54.94M | (m) | $175.90M | $120.96M | (m) | $2.10B | (m) | $141.56M | (m) | (m) | 2.62% | 1.24× |
| 2022-09-30 | $66.29M | (m) | $180.30M | $114.01M | (m) | $2.01B | (m) | $83.91M | (m) | (m) | 3.30% | 2.15× |
| 2022-06-30 | $15.59M | (m) | $119.03M | $103.44M | (m) | $1.91B | (m) | $54.07M | (m) | (m) | 0.82% | 2.20× |
| 2022-03-31 | $46.70M | (m) | $145.59M | $98.89M | (m) | $1.88B | (m) | $39.35M | (m) | (m) | 2.48% | 3.70× |
| 2021-12-31 | $208.96M | (m) | $304.54M | $95.58M | (m) | $1.85B | (m) | $-64.08M | (m) | (m) | 11.32% | -4.75× |
| 2021-09-30 | $182.11M | (m) | $279.97M | $97.87M | (m) | $1.85B | (m) | $15.92M | (m) | (m) | 9.85% | 17.59× |
| 2021-06-30 | $173.42M | (m) | $269.12M | $95.70M | (m) | $1.92B | (m) | $837.21M | (m) | (m) | 9.05% | 0.32× |
| 2021-03-31 | $114.81M | (m) | $214.07M | $99.27M | (m) | $1.84B | (m) | $795.09M | (m) | (m) | 6.22% | 0.27× |
| 2020-12-31 | $-28.95M | (m) | $85.36M | $114.31M | (m) | $1.86B | (m) | $859.10M | (m) | (m) | -1.56% | 0.10× |
| 2020-09-30 | $22.02M | (m) | $156.09M | $134.07M | (m) | $1.86B | (m) | $852.02M | (m) | (m) | 1.18% | 0.18× |
| 2020-06-30 | $-10.34M | (m) | $140.01M | $150.35M | (m) | $1.85B | (m) | $122.26M | (m) | (m) | -0.56% | 1.15× |
| 2020-03-31 | $-68.89M | (m) | $87.94M | $156.82M | (m) | $1.81B | (m) | $114.01M | (m) | (m) | -3.82% | 0.77× |
| 2019-12-31 | $-96.76M | (m) | $48.26M | $145.03M | (m) | $1.70B | (m) | $-23.85M | (m) | (m) | -5.68% | -2.02× |
| 2019-09-30 | $-96.03M | (m) | $40.29M | $136.32M | (m) | $1.60B | (m) | $-42.52M | (m) | (m) | -5.99% | -0.95× |
| 2019-06-30 | $-135.96M | (m) | $17.37M | $153.32M | (m) | $1.53B | (m) | $-110.18M | (m) | (m) | -8.87% | -0.16× |
| 2019-03-31 | $-135.36M | (m) | $7.85M | $143.21M | (m) | $1.52B | (m) | $-89.53M | (m) | (m) | -8.91% | -0.09× |
| 2018-12-31 | $-124.41M | (m) | $20.21M | $144.62M | (m) | $1.49B | (m) | $-77.21M | (m) | (m) | -8.34% | -0.26× |
| 2018-09-30 | $-156.98M | (m) | $-14.55M | $142.43M | (m) | $1.50B | (m) | $-124.95M | (m) | (m) | -10.49% | 0.12× |
| 2018-06-30 | $-158.51M | (m) | $-23.46M | $135.05M | (m) | $1.44B | (m) | $-124.86M | (m) | (m) | -11.02% | 0.19× |
| 2018-03-31 | $-131.12M | (m) | $29.18M | $160.29M | (m) | $1.38B | (m) | $-144.90M | (m) | (m) | -9.48% | -0.20× |
| 2017-12-31 | $-207.98M | (m) | $-8.76M | $199.22M | (m) | $1.31B | (m) | $-117.04M | (m) | (m) | -15.83% | 0.07× |
| 2017-09-30 | $-234.48M | (m) | $-23.58M | $210.90M | (m) | $1.26B | (m) | $-156.37M | (m) | (m) | -18.68% | 0.15× |
| 2017-06-30 | $-266.76M | (m) | $-72.24M | $194.52M | (m) | $1.20B | (m) | $-181.27M | (m) | (m) | -22.21% | 0.40× |
| 2017-03-31 | $-309.09M | (m) | $-136.83M | $172.27M | (m) | $1.18B | (m) | $-563.45M | (m) | (m) | -26.11% | 0.24× |
| 2016-12-31 | $-376.22M | (m) | $-227.84M | $148.38M | (m) | $1.12B | (m) | $-630.21M | (m) | (m) | -33.69% | 0.36× |
| 2016-09-30 | $-496.84M | (m) | $-296.23M | $200.62M | (m) | $1.04B | (m) | $-482.88M | (m) | (m) | -47.56% | 0.61× |
| 2016-06-30 | $-507.54M | (m) | $-288.46M | $219.07M | (m) | $973.71M | (m) | $-531.01M | (m) | (m) | -52.12% | 0.54× |
| 2016-03-31 | $-484.46M | (m) | $-255.43M | $229.03M | (m) | $923.71M | (m) | $-189.44M | (m) | (m) | -52.45% | 1.35× |
| 2015-12-31 | $-449.34M | (m) | $-221.69M | $227.65M | (m) | $889.89M | (m) | $-171.80M | (m) | (m) | -50.49% | 1.29× |
| 2015-09-30 | $-334.06M | (m) | $-180.68M | $153.38M | (m) | $893.78M | (m) | $-310.21M | (m) | (m) | -37.38% | 0.58× |
| 2015-06-30 | $-320.38M | (m) | $-186.38M | $134.00M | (m) | $861.49M | (m) | $-211.84M | (m) | (m) | -37.19% | 0.88× |
| 2015-03-31 | $-323.54M | (m) | $-184.48M | $139.06M | (m) | $802.75M | (m) | $-163.35M | (m) | (m) | -40.30% | 1.13× |
| 2014-12-31 | $-192.37M | (m) | $-73.54M | $118.83M | (m) | $751.04M | (m) | $-133.97M | (m) | (m) | -25.61% | 0.55× |
| 2014-09-30 | $-177.37M | (m) | $-58.06M | $119.31M | (m) | $667.06M | (m) | $-126.16M | (m) | (m) | -26.59% | 0.46× |
| 2014-06-30 | $-166.79M | (m) | $-59.19M | $107.59M | (m) | $627.09M | (m) | $-186.63M | (m) | (m) | -26.60% | 0.32× |
| 2014-03-31 | $-131.95M | (m) | $-54.48M | $77.47M | (m) | $572.11M | (m) | $-174.66M | (m) | (m) | -23.06% | 0.31× |
| 2013-12-31 | $-124.76M | (m) | $-59.63M | $65.12M | (m) | $548.49M | (m) | $-176.35M | (m) | (m) | -22.75% | 0.34× |
| 2013-09-30 | $-85.69M | (m) | $-36.35M | $49.34M | (m) | $533.55M | (m) | $-167.38M | (m) | (m) | -16.06% | 0.22× |
| 2013-06-30 | $-63.79M | (m) | $-12.65M | $51.15M | (m) | $524.79M | (m) | $-119.71M | (m) | (m) | -12.16% | 0.11× |
| 2013-03-31 | $-57.47M | (m) | $-7.25M | $50.22M | (m) | $512.00M | (m) | $-130.19M | (m) | (m) | -11.22% | 0.06× |
| 2012-12-31 | $-26.96M | (m) | $17.61M | $44.57M | (m) | $500.72M | (m) | $-114.35M | (m) | (m) | -5.38% | -0.15× |
| 2012-09-30 | $-33.91M | (m) | $5.45M | $39.36M | (m) | $476.63M | (m) | $-88.07M | (m) | (m) | -7.11% | -0.06× |
| 2012-06-30 | $-80.64M | (m) | $95.00K | $80.73M | (m) | $461.94M | (m) | $-100.37M | (m) | (m) | -17.46% | -0.00× |
| 2012-03-31 | $-58.08M | (m) | $15.08M | $73.16M | (m) | $448.55M | (m) | $-73.44M | (m) | (m) | -12.95% | -0.21× |
| 2011-12-31 | $-54.47M | (m) | $18.75M | $73.22M | (m) | $441.36M | (m) | $-53.84M | (m) | (m) | -12.34% | -0.35× |
| 2011-09-30 | $-72.13M | (m) | $3.15M | $75.28M | (m) | $435.13M | (m) | $-39.29M | (m) | (m) | -16.58% | -0.08× |
| 2011-08-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | $-24.92M | (m) | $3.34M | $28.26M | (m) | $419.45M | (m) | $195.70M | (m) | (m) | -5.94% | 0.02× |
| 2011-03-31 | $-29.60M | (m) | $12.00M | $41.59M | (m) | $400.77M | (m) | $200.30M | (m) | (m) | -7.39% | 0.06× |
| 2010-12-31 | $-30.71M | (m) | $18.75M | $49.46M | (m) | $376.27M | (m) | $205.82M | (m) | (m) | -8.16% | 0.09× |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $-2.07M | (m) | $87.73M | $89.80M | (m) | $324.66M | (m) | $-488.00K | (m) | (m) | -0.64% | -179.78× |
| 2009-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-12-31 | $-65.54M | (m) | $-9.18M | $56.37M | (m) | $296.49M | (m) | $30.83M | (m) | (m) | -22.11% | -0.30× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |